Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 981 to 990 of 1543 total matches.

Alirocumab (Praluent) to Lower LDL-Cholesterol

   
The Medical Letter on Drugs and Therapeutics • Aug 17, 2015  (Issue 1475)
., atorvastatin 40-80 mg), which generally results in 114 The Medical Letter ® Vol. 57 (1475) August 17, 2015 ...
The FDA has approved the subcutaneously injected PCSK9 (proprotein convertase subtilisin kexin type 9) inhibitor alirocumab (Praluent – Sanofi/Regeneron) as an adjunct to diet and maximally tolerated statin therapy for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease who require additional lowering of LDL-cholesterol (LDL-C). It was not approved for general use in statin-intolerant patients. Alirocumab is the first PCSK9 inhibitor to be approved in the US. Evolocumab (Repatha – Amgen), another PCSK9 inhibitor, was...
Med Lett Drugs Ther. 2015 Aug 17;57(1475):113-5 |  Show IntroductionHide Introduction

Tiotropium/Olodaterol (Stiolto Respimat) for COPD

   
The Medical Letter on Drugs and Therapeutics • Nov 23, 2015  (Issue 1482)
in trial 2). Responses were maintained for 52 weeks. 162 The Medical Letter ® Vol. 57 (1482) November 23 ...
The FDA has approved a fixed-dose, orally inhaled combination of the long-acting anticholinergic tiotropium and the long-acting beta2-adrenergic agonist olodaterol (Stiolto Respimat — Boehringer Ingelheim) for long-term, once-daily, maintenance treatment of airflow obstruction in chronic obstructive pulmonary disease (COPD). It is not approved for treatment of acute exacerbations of COPD or for treatment of asthma. Tiotropium (Spiriva Handihaler, Spiriva Respimat) and olodaterol (Striverdi Respimat) are also available separately for once-daily treatment of...
Med Lett Drugs Ther. 2015 Nov 23;57(1482):161-2 |  Show IntroductionHide Introduction

Genvoya - A New 4-Drug Combination for HIV

   
The Medical Letter on Drugs and Therapeutics • Feb 15, 2016  (Issue 1488)
improvements in BMD at the spine (+1.56% vs -0.44%) and hip (+1.47% vs -0.34%).7 20 The Medical Letter ® Vol ...
The FDA has approved Genvoya (Gilead), a fixed-dose combination of the integrase strand transfer inhibitor (INSTI) elvitegravir, the pharmacokinetic enhancer cobicistat, and the nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) emtricitabine and tenofovir alafenamide, for treatment of HIV-1 infection in patients ≥12 years old. This is the first approval for tenofovir alafenamide (TAF), a tenofovir prodrug. Stribild, a fixed-dose combination of elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (TDF), was approved in 2012.
Med Lett Drugs Ther. 2016 Feb 15;58(1488):19-21 |  Show IntroductionHide Introduction

Lesinurad (Zurampic) for Gout-Associated Hyperuricemia

   
The Medical Letter on Drugs and Therapeutics • Nov 21, 2016  (Issue 1508)
The Medical Letter ® Vol. 58 (1508) November 21, 2016 DRUG INTERACTIONS — Lesinurad is metabolized by CYP2C9 ...
The FDA has approved lesinurad (Zurampic – Ironwood), a uric acid transporter 1 (URAT1) inhibitor, for adjunctive treatment of gout-associated hyperuricemia in patients whose serum uric acid levels fail to reach goal with xanthine oxidase inhibitor monotherapy.
Med Lett Drugs Ther. 2016 Nov 21;58(1508):148-50 |  Show IntroductionHide Introduction

Inflectra - An Infliximab Biosimilar

   
The Medical Letter on Drugs and Therapeutics • Jan 30, 2017  (Issue 1513)
, and then every 8 weeks was compared to the same dosage of 24 The Medical Letter ® Vol. 59 (1513) January 30 ...
The FDA has approved infliximab-dyyb (Inflectra – Pfizer; marketed as Remsima in some countries), as a biosimilar of the TNF inhibitor infliximab (Remicade). Infliximab-dyyb was approved in the European Union (EU) in 2013 and in Canada in 2014. It is the second biosimilar to be approved by the FDA. Filgastrim-sndz (Zarxio), a recombinant human granulocyte colony-stimulating factor, was the first.
Med Lett Drugs Ther. 2017 Jan 30;59(1513):23-5 |  Show IntroductionHide Introduction

Lofexidine (Lucemyra) for Opioid Withdrawal

   
The Medical Letter on Drugs and Therapeutics • Jul 16, 2018  (Issue 1551)
discontinuation of lofexidine, however, can cause marked rebound hypertension. 116 The Medical Letter ® Vol. 60 ...
The FDA has approved lofexidine (Lucemyra – US WorldMeds/Salix), a centrally acting alpha2 receptor agonist, to manage withdrawal symptoms in adults abruptly stopping opioid use. Available in the UK since 1992, lofexidine is the first nonopioid to be approved in the US for management of opioid withdrawal symptoms. Clonidine (Catapres, and generics), another central alpha2 receptor agonist, has been used off-label for this indication for many years.
Med Lett Drugs Ther. 2018 Jul 16;60(1551):115-7 |  Show IntroductionHide Introduction

Tildrakizumab (Ilumya) - Another IL-23 Antagonist for Psoriasis

   
The Medical Letter on Drugs and Therapeutics • Jan 14, 2019  (Issue 1563)
The Medical Letter ® Vol. 61 (1563) January 14, 2019 guselkumab, tildrakizumab has not been associated ...
Tildrakizumab-asmn (Ilumya – Sun), an interleukin (IL)-23 antagonist, has been approved by the FDA for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Tildrakizumab is the second selective IL-23 antagonist to be approved for this indication; guselkumab (Tremfya) was the first.
Med Lett Drugs Ther. 2019 Jan 14;61(1563):4-6 |  Show IntroductionHide Introduction

Dupilumab (Dupixent) for Asthma

   
The Medical Letter on Drugs and Therapeutics • Jan 14, 2019  (Issue 1563)
was effective irrespective of baseline blood 7 The Medical Letter ® Vol. 61 (1563) January 14, 2019 ...
The FDA has approved the subcutaneously injected monoclonal antibody dupilumab (Dupixent – Sanofi/Regeneron) for add-on maintenance treatment of patients ≥12 years old with moderate to severe asthma with an eosinophilic phenotype or with oral corticosteroid-dependent asthma. Dupilumab was approved earlier to treat adults with moderate to severe atopic dermatitis inadequately controlled with topical therapies.
Med Lett Drugs Ther. 2019 Jan 14;61(1563):6-8 |  Show IntroductionHide Introduction

Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Feb 25, 2019  (Issue 1566)
of this material is strictly prohibited. For further information call: 800-211-2769 27 The Medical Letter ® Vol ...
Since 2008, because of safety concerns, the FDA has mandated that long-term cardiovascular outcomes trials be conducted for all new drugs for type 2 diabetes. Reductions in the incidence of macrovascular complications in these trials with some sodium-glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists in patients at risk for cardiovascular disease (see Table 1) have led to new recommendations.
Med Lett Drugs Ther. 2019 Feb 25;61(1566):26-8 |  Show IntroductionHide Introduction

Prucalopride (Motegrity) for Chronic Idiopathic Constipation

   
The Medical Letter on Drugs and Therapeutics • Jun 03, 2019  (Issue 1573)
The Medical Letter ® Vol. 61 (1573) June 3, 2019 ADVERSE EFFECTS — In the 6 placebo-controlled clinical ...
The FDA has approved the 5-HT4 receptor agonist prucalopride (Motegrity – Shire) for treatment of chronic idiopathic constipation (CIC) in adults. Prucalopride is the only drug currently approved in the US for treatment of CIC that stimulates colonic peristalsis. It has been available in Europe and Canada for several years.
Med Lett Drugs Ther. 2019 Jun 3;61(1573):86-8 |  Show IntroductionHide Introduction